TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS).

Michael R Hodges et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.